Loading stock data…
Coherus Oncology, Inc. (CHRS)
$1.45-0.05 (-3.33%)
Market ClosedLast close Jun 29
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Coherus Oncology, Inc. in the Healthcare sector is trading at $1.45 with a market capitalization of $228M. Wall Street consensus targets $7.80 (5 analysts), implying a +437.9% move over the next 12 months. The stock is currently 45% below its 52-week high of $2.62, remaining 9.9% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +437.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.31M↓ | $12.75M↑ | $11.57M↑ | $10.25M↑ | $7.60M |
| Gross Profit | $8.50M↓ | $8.70M↑ | $7.85M↑ | $6.86M↑ | $4.95M |
| Operating Income | -$36.15M↑ | -$45.88M↓ | -$44.33M↑ | -$45.49M↓ | -$45.44M |
| Net Income | -$38.33M↓ | -$37.64M↓ | -$35.53M↓ | $297.77M↑ | -$56.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$228.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
236.91%
Volume
Today's trading volume
1.03M
Recent News
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Coherus Oncology, Inc. ( NASDAQ:CHRS ), with the analysts...
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary
Moby summary of Coherus Oncology, Inc.'s Q1 2026 earnings call
Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ...
Coherus Oncology Inc (CHRS) reports a 61% year-over-year increase in LOQTORZI sales, bolstered by strategic partnerships and a successful equity offering, despite weather-related challenges.
Coherus Oncology Q1 Earnings Call Highlights
Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year. On the company’s first-quarter 2026 earnings call
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?